In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Value Lab: Moving Value-Based Health Care From Theory To Practice

Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.

BioPharmaceutical Reimbursement Private Payers

Medtech Value Brands: Stepping Down May Boost The Top Line

The medtech industry has traditionally grown through innovation – new products with improved features and benefits have fueled revenue growth. However, innovation alone does not garner the price premium it once did, and manufacturers must decide whether to pursue a value brand strategy alongside their traditional premium brand, says global management consulting firm Simon-Kucher & Partners.

Pricing Strategies Business Strategies Medical Device

Podcast: Big Pharma Licensing Trends

Big pharma comprises a smaller proportion of the deals market than mid-size and smaller biopharmas or biotechs, but it is the biggest spender. A free audio/video excerpt on big pharma licensing trends from Datamonitor Healthcare's webinar, "From R&D Investment To Externalization: Where Is The Pharma Industry Maximizing Value?"

Deals Market Intelligence BioPharmaceutical
Advertisement


 

Recent Tweets from In Vivo


 

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Admedus CEO Ready To Transform Company Again With TAVR

The ups, downs – and nearly outs – of ASX-listed health technologies manufacturer and distributor Admedus have made compelling reading in the past two years, but CEO Wayne Paterson has brought a competitive edge to a company that was lacking focus. Now he is looking to raise the bar again, aiming to use the company's proprietary Adapt patch technology in the TAVR space, while also pressing on with strategic plans for the therapeutic vaccines portfolio and adding scale.

Business Strategies Cardiovascular

Fortress Biotech: A Drug Financing Experiment Expands

Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.

Business Strategies Financing

Olympus Dives Back Into M&A With Image Stream Medical Buy

When Olympus Corp. re-entered the M&A arena after five years of "back to the basics," it was via the purchase of a company that meets every parameter of its requirements. Nacho Abia says that OR integrator Image Stream Medical should also help the Japanese multinational stay on course to meet value-based – and ambitious mid-term sales – targets.

Deals M & A

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

HCV Patient Access: Trek Therapeutics Takes The Road Less Traveled

Trek Therapeutics, a three-year old biotech founded by a group of virology veterans, is testing the conventional wisdom in seeking to carve out a potential $17 billion business in the hotly contested hepatitis C space.

BioPharmaceutical Infectious Diseases

Killer Cures: Industry Heavyweights Make Their Presence Felt In Cell And Gene Therapy

Cell and gene therapies, described as the most exciting developments in the life sciences industry, pick up more momentum with every passing month. The spiraling enthusiasm for an activity that will change how health care is delivered was captured by GE, GSK and other key industry players at a leading UK life sciences industry meeting in spring 2017.

Business Strategies Cancer

Liquid Biopsy On Course To Transform Cancer Management

Liquid biopsies look set to revolutionize the management of cancer patients.  A significant application could come in immuno-oncology, given the rapid uptake of IO drugs and the need to monitor changes in a patient’s immune profile over time to guide therapy selection.

Cancer Business Strategies

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Execs On The Move, July 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership BioPharmaceutical

Hack Attack: Biopharma Cyber Chiefs Fight Back

The threat of cyberattacks on biopharma’s extensive information assets is moving to the top of the list of business risks confronting senior C-suite management. In Vivo’s Roundtable panel of leading biopharma CISOs reviews what to do and what it will take to convince others in senior management to buy into a challenge that still remains largely below the surface.

BioPharmaceutical Leadership

Execs On The Move, June 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership BioPharmaceutical

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

UK Medtech One Year Post-Brexit Vote: Still In The Land Of Uncertainty

The UK's Brexit and a failed Conservative Party election strategy last month weigh heavily on the minds of local medtech businesses, looking ahead nervously at the type of trade deal the UK might finally strike with the EU. They could be waiting awhile, because the When and What are still not yet apparent – never mind that the Why still rankles with many UK medtechs. That much is clear from a brand new survey of companies, which also reveals the primacy of NHS access.

United Kingdom Brexit

2017 Fair Pricing Forum: The Message For Pharma CEOs

Pharmas were in the minority at WHO's Fair Pricing Forum, but ZS' Ed Schoonveld says that other attendees sent some messages that pharma CEOs should heed.

BioPharmaceutical Market Access

UK General Election Misjudgment: Dismay For May Who Finds The Politics Of Greed Don't Pay

The smart money had increasingly been on a hung parliament in the UK, with the ruling Conservative party being punished for several policy slip-ups, perceived dithering by Prime Minister Theresa May and her insistence on a clean and hard Brexit led by her alone. The June 8 election did not need to be called, and today, May is ruing the fact that she has lost both the party's absolute majority and her mandate to lead on a hard Brexit.

United Kingdom Brexit

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

In Vivo's Deals Of The Month, June 2017

In Vivo's editors pick June's most significant deals, including Idorsia's IPO and Medtronic's outcomes-based contract with Aetna. (Free article.)

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, July 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.

Deals BioPharmaceutical

Deals In Depth: May 2017

AstraZeneca could pay up to $2.1 billion in an Anticalin protein therapeutics deal with Pieris, centered around respiratory diseases. In the latest CRO takeover, Thermo Fisher Scientific bought Patheon for $7.2 billion. Biopharma financing declined in May compared with April, mostly due to a decrease in public offering value.

BioPharmaceutical Medical Device
UsernamePublicRestriction

Register

Advertisement